Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
7
×
boston blog main
boston top stories
7
×
boulder/denver blog main
boulder/denver top stories
cancer
cancer immunotherapy
7
×
detroit blog main
detroit top stories
eli lilly
7
×
indiana blog main
indiana top stories
life sciences
national
7
×
national blog main
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
7
×
pfizer
startups
clinical trials
deals
fda
investing
alzheimer's disease
biogen
bristol-myers squibb
medicare
What
bio
roundup
companies
drug
alzheimer’s
growing
life
nash
new
news
pharmaceutical
price
prices
science
typically
week
alliance
annual
approval
approved
arena’s
assessed
attention
bails
biogen’s
biopharmaceutical
biotech
bounty
brand
bridgebio
bristol
buy
calls
capital
car
changing
cig
color
comeback
communities
Language
unset
Current search:
national
×
biotech
×
" cancer immunotherapy "
×
" eli lilly "
×
" wisconsin top stories "
×
" boston top stories "
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Bio Roundup: NASH News, Merck Strikes, Digital Tokens & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Fail, Drug Price Plan, Gene Therapies & More
@xconomy.com
5 years ago
Bio Roundup: Moderna’s IPO, Arena’s Comeback, E-Cig Survey & More
@xconomy.com
5 years ago
Bio Roundup: Alzheimer’s Puzzle, ESMO Assessed, Drug Prices & More